XAV-19: Clinical Trials

2 trials of XAV-19, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Terminated 1
Phase 31Terminated 1

Follow XAV-19: new trials by email Literature Review of XAV-19 trials Research Report on XAV-19

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19
XAV-19, Placebo - COVID-19
Phase 2 / Phase 3TerminatedXenothera SAS2902021-04-282023-01-23
Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia
XAV-19, Placebo - SARS Virus
Phase 2CompletedNantes University Hospital4162020-09-012022-03-25

Conditions studied

COVID-19 (2)  ·  Lymphoma, Follicular (1)  ·  Pneumonia (1)  ·  Severe Acute Respiratory Syndrome (1)

Sponsors

Nantes University Hospital (1)  ·  Xenothera SAS (1)

Countries

Bulgaria (1)  ·  France (1)  ·  Greece (1)  ·  Martinique (1)  ·  Reunion (1)  ·  Romania (1)  ·  Spain (1)  ·  Turkey (Türkiye) (1)

Top investigators

Benjamin Gaborit (1)

Results publications

PMID 33750432, PMID 34181475, PMID 34473343, PMID 36700518, PMID 38694503